Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by progressive and selective death of dopaminergic neurons. Orexin-A is involved in many biological effects of the body. It has been reported that orexin-A has protective effects in cellular models of PD. However, little is known about the protective effects of orexin-A in animal parkinsonian models and the cellular mechanism has not yet been fully clarified. The aim of this study was to evaluate the effects of orexin-A in MPTP mice model of PD as well as the possible neuroprotective mechanisms of orexin-A on dopaminergic neurons. The results from animal experiments demonstrated that orexin-A attenuated the loss of dopaminergic neurons and the decrease of tyrosine hydroxylase (TH) expression in the substantia nigra, normalized the striatal dopaminergic fibers, and prevented the depletion of dopamine and its metabolites in the striatum. MPTP-treated mice showed cognitive impairments accompanied with significant motor deficiency. Orexin-A improved MPTP-induced impairments in both motor activity and spatial memory. Importantly, orexin-A increased the protein level of brain-derived neurotrophic factor (BDNF) in dopaminergic neurons of the substantia nigra. Furthermore, the protective effects of orexin-A on MPTP parkinsonian mice could be blocked by orexinergic receptor 1 (OX1R) antagonist, SB334867. In another set of experiments with SH-SY5Y dopaminergic cells, orexin-A significantly induced the expression of BDNF in a dose and time-dependent manner. The upregulation of BDNF is mainly concerned with PI3K and PKC signaling pathways via OX1R. The present study demonstrated that orexin-A exerted neuroprotective effects on MPTP parkinsonian mice, which may imply orexin-A as a potential therapeutic target for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurons containing hypocretin (orexin) project to multiple neuronal systems
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09996.1998 · Cited by 3,466 · cited 2×
“Orexins, consisting of orexin-A and orexin-B, belong to hypothalamic neuropeptides derived from a common precursor named prepro-orexin (Peyron et al., 1998; Sakurai et al., 1998).”
BackgroundDifferential expression of orexin receptors 1 and 2 in the rat brain
Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1190 · Cited by 1,659
Hypocretin (orexin) cell loss in Parkinson's disease
Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566
Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
Hypocretin (orexin) loss in Parkinson's disease
Fronczek, R., Overeem, S., Lee, S. Y. Y., Hegeman, I. M., van Pelt, J., van Duinen, S. G., Lammers, G. J., & Swaab, D. F. (2007) · Brain · doi:10.1093/brain/awm090 · Cited by 463
Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., & Teixeira, A. L. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5357-2 · Cited by 299 · cited 2×
“In addition, epidemiological studies showed that low serum levels of BDNF are associated with the motor (Scalzo et al., 2010) and cognitive impairments (Angelucci et al.”
BackgroundInteractions between the NR2B Receptor and CaMKII Modulate Synaptic Plasticity and Spatial Learning
Zhou, Y., Takahashi, E., Li, W., Halt, A., Wiltgen, B., Ehninger, D., Li, G.-D., Hell, J. W., Kennedy, M. B., & Silva, A. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4486-07.2007 · Cited by 179 · cited 1×
“Curtains surrounded the pool with distinct cues sticking on (Zhou et al., 2007 and Liu Q. et al., 2018).”
BackgroundYang, L., Zou, B., Xiong, X., Pascual, C., Xie, J., Malik, A., Xie, J., Sakurai, T., & Xie, X. (. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3200-12.2013 · Cited by 153
Porritt, M. J., Batchelor, P. E., & Howells, D. W. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.030 · Cited by 135 · cited 1×
“, 2000), and the inhibition of BDNF expression leads to the loss of nigral dopaminergic neurons (Porritt et al., 2005; Fumagalli et al., 2006).”
BackgroundTsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N. (1995) · Neurosurgery · doi:10.1227/00006123-199510000-00018 · Cited by 134
Cited by
The Role of Oxygen Homeostasis and the HIF-1 Factor in the Development of Neurodegeneration
Mitroshina, E. V., & Vedunova, M. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094581 · Cited by 48
Huang, L., Kang, J., Chen, G., Ye, W., Meng, X., Du, Q., & Feng, Z. (2022) · Aging · doi:10.18632/aging.204290 · Cited by 23
Roveta, F., Marcinnò, A., Cremascoli, R., Priano, L., Cattaldo, S., Rubino, E., Gallo, E., Boschi, S., Mauro, A., & Rainero, I. (2022) · Neurological Sciences · doi:10.1007/s10072-021-05250-x · Cited by 6
Metadata
- Authors
- Liu, M.-F., Xue, Y., Liu, C., Liu, Y.-H., Diao, H.-L., Wang, Y., Pan, Y.-P., & Chen, L.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-11-15
- Volume
- 12
- Pages
- 835-835
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2898978796
- Cited by
- 72
- References
- 13
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease. https://app.cochat.ai/papers/10.3389/fnins.2018.00835
- The paper
- Liu, M.-F., Xue, Y., Liu, C., Liu, Y.-H., Diao, H.-L., Wang, Y., Pan, Y.-P., & Chen, L. (2018). Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2018.00835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.